Search results for: Henry Fong
Filter search results
Henry Fong
2 October 2024
Henry joined OHE in October 2024 as a Graduate Economist. He holds an MPharm degree from University College London and is a registered pharmacist with the General Pharmaceutical Council (GPhC)….
Lancelot Henry de Frahan – 2022 Prize Finalist
18 January 2023
Dr. Lancelot Henry de Frahan, PhD, post–doctoral researcher at the Economics department at the University of Chicago. His research specializes in price theory, labor economics and public finance with a…
Biosimilars and Data Exclusivity
8 June 2010
…on the OHE seminar and summarises the remarks of Prof Henry Grabowski of Duke University. Data exclusivity is the period of time after a drug is approved before a biosimilar…
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Share this: Download publication Hania El Banhawi Henry Fong Matthias Hofer Lotte Steuten Compared to shorter acting therapies, long-acting therapies might be overlooked and hold potential for patients, healthcare systems…
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
Share this: Download publication Henry Fong George Bray Grace Hampson Lotte Steuten Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually and…
Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
5 June 2025
Share this: Henry Fong Chris Sampson Grace Hampson CERSI-PGx is the Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics, led by the University of Liverpool and funded by…
Our team
…Economist Ellie Tunnicliffe Economist SooChin Yen Economist Paul Oyalo Economist Brittany Darrow Economist Henry Fong Economist Angus Macfarlane Graduate Economist Louis Zanden Graduate Economist Libby Tungate Fellow Aisha Aidarous Fellow…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
Share this: Download publication Henry Fong Priscila Radu Nadine Henderson Martina Garau Lotte Steuten Key messages Tumour-agnostic (TA) therapies disrupt conventional oncology paradigms by targeting molecular alterations rather than tumour…